medigraphic.com

2010, Number 3

<< Back Next >>

Enf Infec Microbiol 2010; 30 (3)

Kaposi's sarcoma in oral cavity

Frías SJA, Julián CA

Language: Spanish
References: 46
Page: 100-105
PDF size: 77.39 Kb.


ABSTRACT

Kaposi’s sarcoma (KS) is one of the neoplasms associated with human immunodeficiency virus (HIV) and CD4 cell depletion. In Mexico there are few research studies on these lesions. KS related to HIV/AIDS is the early finding and useful marker of progression of immunodeficiency, in advanced cases it is associated with skin lesions. KS in the oral cavity, hard palate has proven to be the main site of localization of these lesions, followed by the soft palate, gums and tonsils, its clinical presentation is varied. Prevalence of KS has declined trough Highly Effective Antiretroviral Therapy (HAART).


REFERENCES

  1. www.ss.gob.mx//.censida

  2. Baccaglini L, Atkinson JC., Patton LL y cols. “Management of oral lesions in HIV-positive patients”. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2007;103:1-23.

  3. Ramírez Amador V, Esquivel-Pedraza L, Sierra-Madero J y cols. “The changing clinical spectrum of Human Immunodeficiency Virus (HIV)-related oral lesions in 1000 consecutive patients: A 12-year study in a referral center in Mexico”. Medicine 2003; 82:39-50.

  4. Patton L, McKaig R, Strauss R y cols. “Changing prevalence of oral manifestations of human immunodeficiency virus in the era of protease inhibitor therapy”. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2000; 89:299-304.

  5. Ramírez-Amador V, Esquivel-Pedraza L, Ponce D y cols. “Prognostic value of oral candidosis and hairy leukoplakia in 111 Mexican HIV-infected patients”. J Oral Pathol Med 1996; 25:206–211.

  6. Hodgson T. “HIV-associated oral lesions: prevalence in Zambia”. Oral Diseases 1997; 1:46-50.

  7. Birnbaum W, Hodgson T, Reichart P y cols. “Prognostic significance of HIV associated oral lesions and their relation to therapy”. Oral Diseases 2002; 8:110-114.

  8. Conant M, Opp K, Portez D y cols. “Reduction of Kaposi's sarcoma lesions following treatment of AIDS with ritonavir”. AIDS 1997;11:1300-1301.

  9. Kaposi M. “Classics in Oncology: Idiopathic multiple pigmented sarcoma of the skin”. Arch Dermatol Syphil 1972; 4:265-273.

  10. Iscovich J, Boffetta P, Franceschi S y cols. “Classic Kaposi sarcoma”. Cancer 2000; 88: 500-517.

  11. Kedes D, Ganem D, Ameli N y cols. “The prevalence of serum antibody to human herpesvirus 8 (Kaposi Sarcomam-associated herpesvirus) among HIV-seropositive and high-risk HIV-seronegative women”. JAMA 1997; 277:478-481.

  12. Haverkos H. “Viruses, chemicals and co-carcinogenesis”. Oncogene 2004; 23: 6492-6499.

  13. Ziegler J, Newton R, Bourboulina D y cols. “Risk factors for Kaposi´s sarcoma: a case-control study of HIV-seronegative people in Uganda”. Int J Center 2003; 103:233-240.

  14. Haverkos H. “Multifactorial etiology of Kaposi´s sarcoma: a hypothesis. Indian Academy of Sciences”. J Biosci 2008; 33:643-651.

  15. Osmond D, Buchbinder S, Cheng A y cols. “Prevalence of Kaposi sarcoma- associated herpesvirus infection in homosexual men at beginning of and during the HIV epidemic”. JAMA 2002; 287:221-225.

  16. Mocroft A, Kirk O, Clumeck N y cols. “The changing pattern of Kaposi sarcoma in patients with HIV, 19942003”. Euro SIDA 2004; 100: 2644-2654.

  17. Ramírez-Amador V, Anaya-Saavedra G, Calva J y cols. “HIV related oral lesions, demographic factors, clinical staging and anti-retroviral use”. J Arc Med 2006; 37:646-654.

  18. Ambrogiak J, Blackbourne D, Hemdier B y cols. “Herpes-like sequence HIV-infected and uninfected Kaposi’s sarcoma patients”. Science 1995;268:582-584.

  19. Mc Nutt NS, Fletcher V, Conant MA. “Early lesions of Kaposi’s sarcoma in homosexual men: An ultrastructural comparisson with other vascular proliferation’s in skin”. Am J Pathol 1983; 1: 62-63.

  20. Friedman K Lanberstein. “Disseminated Kaposi’s Sarcoma in homosexual men”. Ann Intern Med 1982; 96:693-700.

  21. Carvajal A, Figueredo A, Rebolledo M y cols. “Sarcoma de Kaposi en cavidad oral en 25 pacientes con SIDA”. Boletín Venez Infectol 2008;19:50-55.

  22. Phelan JA. “Oral manifestation of human immunodeficiency virus infection”. Med Clin NA 1997; 81:511-531.

  23. Haverkos HW, Drotman DP, Hanson D. “Epidemiology of AIDS-related Kaposi’s sarcoma: An update”. Int Conf AIDS. 1993; 9:398-399.

  24. Jacobson LP, Muñoz A, Fox R y cols. “Incidence of Kaposi’s sarcoma in a cohort of homosexual men infected with human immunodeficiency virus type I”. J Acquired Inmune Defic Syndr 1990;3:24-26.

  25. Ramirez-Amador V, González M, de la Rosa E y cols. “Oral findings in Mexican AIDS patients with cancer”. J Oral Pathol Med 1993; 22:87-91.

  26. Ranganathan K, Hemalatha R. “Oral lesions in hiv infection in developing countries: An overview”. Adv Dent Res 2006;19:63-68.

  27. Chang Y, Moore P. “Kaposi’s sarcoma (KS)-associated herpesvirus and its role in KS”. Infect Agents Dis 1996;5: 215–222.

  28. Fricarra G, Berson A, Silverman S y cols. “Kaposi’s sarcoma oftheoralcavity.Astudyof134patientswithareviewofthe pathogenesisepidemiology,clinicalaspectsandtreatment”. Oral Surg Oral Med Oral Pathol 1988;66:543-550.

  29. 29 Keeney K, Abaza N, Tidwel O y cols. “Oral Kaposi’s sarcoma in acquired immune deficiency syndrome”. J Maxillofac Oral and Surg 1987; 45:815-821.

  30. Bi-shi FU, Bao-lin LI, Xin-xing y cols. “Expression of Kapos's Sarcoma-associated herpesvirus ORFK8.1 and its preliminary diagnostic application”. Virologica Sinica 2009, 24:202-208.

  31. Krown S, Testa M, Huang J. “Validation of the AIDS Clinical Treat Group (ACTG) stagings classifications for AIDS- Associated Kaposi’s sarcoma”. Soc Clin Oncol 1996;15:303-310.

  32. Redfield RR, Wright DC. “The Walter Reed Stating Classification for HTLV III/LAV”. 1986;314:131-132.

  33. Enzinger F, Weiss S. “Soft tissue tumors. Malignant vascular tumors”. Mosby 3rd. ed, 1995; 25:658-669.

  34. Revankar S, Sánchez S, Dib OP y cols. “Effect of highly active antiretroviral therapy on recurrent oropharyngeal candidiasis in HIV infected patients”. AIDS 1998; 12:2511-2513.

  35. Glick M, Muzyka B, Lurie D y cols. “Oral manifestations associated with HIV-related disease as markers for immune suppression and AIDS”. Surg Oral Med Oral Pathol Oral Radiol Endod 1994;77:344-346.

  36. Flaitz C, Nichols C, Hicks M. “Oral malignancies diagnosed in an HIV dedicated dental clinic”. J Texas Dental 1996;113:49-57.

  37. Cheung T, Remick S, Azarnia N y cols. “AIDS-related Kaposi’s sarcoma: A phase II study of liposomal doxorubicin”. Clinical Cancer Research 1999;5:3432-3437.

  38. TulpuleA,GroopmanJ,SavilleMycols.“Multicentertrial of low-dose paclitaxel in patients with advanced AIDSrelated Kaposi sarcoma”. Cancer 2002;95:147-154.

  39. Cattelan A, Trevenzoli M, Aversa S. “Novel pharmacological therapies for the treatment of AIDS-related Kaposi’s sarcoma”. Expert Opinion Invest Drugs 2004;13:501 513.

  40. Olweny C, Borok M, Gudza I y cols. “Treatment of AIDSassociated Kaposi’s sarcoma in Zimbabwe: results of a randomized quality of life focused clinical trial”. J Inter Cancer 2005;113: 632-639.

  41. Hodgson T, Kondowe W, Molyneux E. y cols. “Thalidomide for palliation of Kaposi’s sarcoma in Malawian children. Proceedings of the 5th World Workshop on Oral Health and Disease in AIDS 2004, Phuket, Thailand”. Advances in Dental Research 2005.

  42. Tavio M, Nasti G, Spina M. “Highly active anti-retroviral therapy in HIV-related Kaposi’s sarcoma”. Ann Oncol 1998; 9:923-935.

  43. Hernández D, Pérez J. “Tratamiento del sarcoma de Kaposi epidémico”. Rev Venez Oncol 1993; 1:18-23.

  44. Eptein JB, Lozada NF, Mc Leodwa y cols. “Oral Kaposi’s sarcoma in acquired immunodeficiency syndrome. Review of management and report of the efficacy of intralesional vimblastina”. Cancer. 1989;64:2424-2430.

  45. Zoi P, Jones J, Morgan P y cols. “Oral Kaposi sarcoma: a case of immune reconstitution inflammatory syndrome”. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2009;108:70-75.

  46. Coogan M, Greenspan J, Challacombe S. “Oral lesions in infection with human immunodeficiency virus”. Bull World Health Organ 2005; 83:700-706.




2020     |     www.medigraphic.com